The Network’s investment
in early-stage research projects often results in the creation
of intellectual property (IP). This IP has been out-licensed
to existing biopharmaceutical companies, or has formed the
foundation of new start-up companies. The following is a list
of biopharmaceutical companies that have benefited from network
IP and management services.
Xenon
Xenon Genetics is a privately owned, genomics-based drug discovery
and development company engaged in identifying genes and other
drug targets associated with human disease and developing
pharmaceutical therapies based on these genetically-derived
targets. Xenon’s drug discovery programs are targeted
toward the development of therapies for cardiovascular, metabolic
and neurological diseases.
Aegera
Aegera Therapeutics is building an integrated world-class
biotechnology company focused on signal transduction and apoptosis.
Formed by the merger of Apoptogen and Exogen Neurosciences
in May 2000, Aegera’s primary therapeutic focus is in
apoptosis control: killing cancer cells by inducing apoptosis,
rescuing neurons from cell death, and implanting stem cells
to restore function. Aegera focuses on cancer and degenerative
diseases of the central and peripheral nervous systems.
Medigene
MediGene AG, acquired CGDN spin-off company NeuroVir in November
2000. Medigene is a
publicly traded German biopharmaceutical firm with headquarters
in Martinsried, Munich, and a subsidiary, MediGene, Inc.,
in San Diego, California. MediGene combines a broad technology
platform with products in pre-clinical and clinical development.
Solutions
by Sequence
Solutions by Sequence, Inc. is a private corporation, owned
by its founding scientists and the Canadian Genetic Diseases
Network, hosted in the Vision Science Research Program by the
University Health Network. The company develops diagnostic tests
for genetic mutations that lead to disease.
Ellipsis Biotherapeutics
Ellipsis is a privately-owned biotechnology company based
in Toronto, Canada. Founded by researchers at Mount Sinai
Hospital and the Hospital for Sick Children, Ellipsis is actively
pursuing genes involved immunological and inflammatory disease.
Aspreva
Aspreva is a global pharmaceutical company that
was created to develop high therapeutic value medicines for
the treatment of rare diseases.
|
